Guselkumab (TREMFYA (R)) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study
Rahman P, Mcinnes I, Deodhar A, Schett G, Mease P, Shawi M, Cua D, Sherlock J, Kollmeier A, Xu X, Jiang Y, Sheng S, Ritchlin C, Mcgonagle D (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 2757-2760
Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY
Authors with CRIS profile
Involved external institutions
Eastern Health
Canada (CA)
University of Glasgow
United Kingdom (GB)
Oregon Health and Science University (OSHU)
United States (USA) (US)
Swedish Medical Center
United States (USA) (US)
Janssen Immunol Global Commercial Strategy Organisation
Canada (CA)
Janssen Pharmaceutica NV
Belgium (BE)
University of Rochester (UR)
United States (USA) (US)
University of Leeds
United Kingdom (GB)
Canada (CA)
University of Glasgow
United Kingdom (GB)
Oregon Health and Science University (OSHU)
United States (USA) (US)
Swedish Medical Center
United States (USA) (US)
Janssen Immunol Global Commercial Strategy Organisation
Canada (CA)
Janssen Pharmaceutica NV
Belgium (BE)
University of Rochester (UR)
United States (USA) (US)
University of Leeds
United Kingdom (GB)
How to cite
APA:
Rahman, P., Mcinnes, I., Deodhar, A., Schett, G., Mease, P., Shawi, M.,... Mcgonagle, D. (2021). Guselkumab (TREMFYA (R)) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study. In ARTHRITIS & RHEUMATOLOGY (pp. 2757-2760). HOBOKEN: WILEY.
MLA:
Rahman, Proton, et al. "Guselkumab (TREMFYA (R)) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2021. 2757-2760.
BibTeX: Download